4.7 Article

An explanation for the low proportion of tuberculosis that results from transmission between household and known social contacts

Journal

SCIENTIFIC REPORTS
Volume 8, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-018-23797-2

Keywords

-

Funding

  1. UK Medical Research Council (MRC)
  2. UK Department for International Development (DFID) under the MRC/DFID Concordat
  3. European Union [MR/P002404/1]
  4. Bill and Melinda Gates Foundation [OPP1084276/OPP1135288, OPP1110334, OPP1137034, OPP1160830, PO 8477-0-600, 4214-LSHTM-Sept15]
  5. MRC Skills Development Fellowship [MR/N014693/1]
  6. European Union
  7. MRC [MR/P002404/1, MR/N014693/1] Funding Source: UKRI
  8. Bill and Melinda Gates Foundation [OPP1137034, OPP1110334, OPP1160830] Funding Source: Bill and Melinda Gates Foundation
  9. Medical Research Council [MR/P002404/1, MR/N014693/1] Funding Source: researchfish

Ask authors/readers for more resources

We currently have little idea where Mycobacterium tuberculosis (Mtb) transmission occurs in high incidence settings. Molecular studies suggest that only around 8-19% of transmission to adults occurs within-household, or between known social-contacts. This contrasts with findings from social-contact studies, which show that substantial proportions of contact time occur in households, workplaces and schools. A mathematical model of social-contact behaviour and Mtb transmission was developed, incorporating variation in susceptibility and infectiousness. Three types of contact were simulated: household, repeated (individuals outside household contacted repeatedly with daily-monthly frequency) and non-repeated. The model was parameterised using data from Cape Town, South Africa, on mean and variance in contact numbers and contact durations, by contact type, and fitted to an estimate of overdispersion in numbers of secondary cases ('superspreading') in Cape Town. Household, repeated, and non-repeated contacts contributed 36%, 13%, and 51% of contact time, and 13%, 8%, and 79% of disease, respectively. Results suggest contact saturation, exacerbated by long disease durations and superspreading, cause the high proportion of transmission between non-repeated contacts. Household and social-contact tracing is therefore unlikely to reach most tuberculosis cases. A better understanding of transmission locations, and methods to identify superspreaders, are urgently required to improve tuberculosis prevention strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Infectious Diseases

Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package-hmer

Danny Scarponi, Andrew Iskauskas, Rebecca A. Clark, Ian Vernon, Trevelyan J. McKinley, Michael Goldstein, Christinah Mukandavire, Arminder Deol, Chathika Weerasuriya, Roel Bakker, Richard G. White, Nicky McCreesh

Summary: Infectious disease models are used by epidemiologists to understand transmission dynamics, predict interventions, and improve disease understanding. However, as the complexity of these models increases, calibration to data becomes more challenging. This study introduces a new software, hmer, which efficiently calibrates complex models for tuberculosis vaccines to over 100 countries. The results show that hmer is a useful tool for epidemiologists to calibrate models and improve predictions.

EPIDEMICS (2023)

Article Public, Environmental & Occupational Health

Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study

Alexandra S. Richards, Bianca Sossen, Jon C. Emery, Katherine C. Horton, Torben Heinsohn, Beatrice Frascella, Federica Balzarini, Aurea Oradini-Alacreu, Brit Haecker, Anna Odone, Nicky McCreesh, Alison D. Grant, Katharina Kranzer, Frank Cobelens, Hanif Esmail, Rein M. G. J. Houben

Summary: This study quantified the pathways of tuberculosis disease progression and regression. It found that after 5 years, 40% of individuals with subclinical tuberculosis recover, 18% die, 14% remain infectious, and the rest have minimal disease at risk of re-progression. For individuals with subclinical disease at baseline, 50% never develop symptoms within 5 years. For those with clinical disease at baseline, 46% die and 20% recover from tuberculosis within 5 years.

LANCET GLOBAL HEALTH (2023)

Article Critical Care Medicine

Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment

Molebogeng X. Rangaka, Mike Frick, Gavin Churchyard, Alberto L. Garcia-Basteiro, Mark Hatherill, Willem Hanekom, Philip C. Hill, Yohhei Hamada, Matthew Quaife, Johan Vekemans, Richard G. White, Frank Cobelens

Summary: This paper discusses the urgent need for new tuberculosis vaccines and improved tuberculosis preventive treatment (TPT) regimens. It examines how HIV vaccine trials have incorporated preventive treatment and proposes trial designs that integrate TPT. The considerations for each design in terms of trial validity, efficiency, participant safety, and ethics are summarized.

LANCET RESPIRATORY MEDICINE (2023)

Article Public, Environmental & Occupational Health

Cost-effectiveness of tuberculosis infection prevention and control interventions in South African clinics: a model-based economic evaluation informed by complexity science methods

Fiammetta Maria Bozzani, Nicky McCreesh, Karin Diaconu, Indira Govender, Richard G. White, Karina Kielmann, Alison D. Grant, Anna Vassall

Summary: An economic evaluation conducted in two clinics in South Africa showed that tuberculosis infection prevention and control measures, including improving ventilation and maximizing the use of existing systems, are cost-effective and should be implemented within the country's health system.

BMJ GLOBAL HEALTH (2023)

Article Infectious Diseases

Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?

Kristin N. Nelson, Gavin Churchyard, Frank Cobelens, Willem A. Hanekom, Philip C. Hill, Benjamin Lopman, Vidya Mave, Molebogeng X. Rangaka, Johan Vekemans, Richard G. White, Emily B. Wong, Leonardo Martinez, Alberto L. Garcia-Basteiro

Summary: Tuberculosis is a leading bacterial cause of death worldwide. Several vaccine candidates are currently in clinical trials to prevent tuberculosis in adolescents and adults. However, current trial designs do not provide information on the overall effect of introducing a vaccine program, including indirect effects. Understanding these effects is crucial for policymakers considering tuberculosis vaccination programs.

LANCET MICROBE (2023)

Article Medicine, General & Internal

New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01(E) and BCG-revaccination

Rebecca A. Clark, Chathika K. Weerasuriya, Allison Portnoy, Christinah Mukandavire, Matthew Quaife, Roel Bakker, Danny Scarponi, Rebecca C. Harris, Kirankumar Rade, Sanjay Kumar Mattoo, Dheeraj Tumu, Nicolas A. Menzies, Richard G. White

Summary: The potential health and economic impact of M72/AS01(E) and BCG-revaccination in India were evaluated. The results showed that M72/AS01(E) vaccine could prevent more tuberculosis cases and deaths compared to BCG-revaccination, and almost all scenarios were cost-effective. However, there is uncertainty regarding the vaccine characteristics that requires further investment.

BMC MEDICINE (2023)

Article Public, Environmental & Occupational Health

Improving the quality of the Global Burden of Disease tuberculosis estimates from the Institute for Health Metrics and Evaluation

Peter J. Dodd, Christopher Finn Mcquaid, Prasada Rao, Ibrahim Abubakar, Nimalan Arinaminpathy, Anna Carnegie, Frank Cobelens, David Dowdy, Kathy Fiekert, Alison D. Grant, Jing Wu, Faith Nekabari Nfii, Nabila Shaikh, Rein M. G. J. Houben, Richard G. White

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2023)

Editorial Material Immunology

An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials

Philip C. Hill, Frank Cobelens, Leonardo Martinez, Marcel A. Behr, Gavin Churchyard, Tom Evans, Andrew J. Fiore-Gartland, Alberto L. Garcia-Basteiro, Willem Hanekom, Molebogeng X. Rangaka, Johan Vekemans, Richard G. White

Summary: The development of a new tuberculosis vaccine is crucial, but the traditional development pathway is a major obstacle. By increasing sample size, simplifying screening criteria and procedures, and strengthening site capacity, phase 3 tuberculosis vaccine trials can be significantly shortened.

JOURNAL OF INFECTIOUS DISEASES (2023)

Letter Immunology

Reply to McShane

Philip C. Hill, Frank Cobelens, Leonardo Martinez, Alberto L. Garcia-Basteiro, Marcel A. Behr, Molebogeng X. Rangaka, Gavin Churchyard, Tom Evans, Willem Hanekom, Richard G. White

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Medicine, General & Internal

The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study

Allison Portnoy, Jean-Louis Arcand, Rebecca A. A. Clark, Chathika K. K. Weerasuriya, Christinah Mukandavire, Roel Bakker, Edith Patouillard, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. G. White, Nicolas A. A. Menzies

Summary: This study aimed to estimate the impact of introducing novel TB vaccines on GDP growth in 105 LMICs. The results showed that introducing new TB vaccines could increase economic growth in these countries, with a more significant effect in countries with higher current TB incidence.

PLOS MEDICINE (2023)

Article Public, Environmental & Occupational Health

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

Allison Portnoy, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Matthew Quaife, Roel Bakker, Ines Garcia Baena, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies

Summary: Introducing novel TB vaccines can reduce the financial burden and household economic risks for low-income individuals with tuberculosis. The health benefits of the vaccines are greatest for the lower income quintiles, reducing income-based inequalities in TB outcomes.

BMJ GLOBAL HEALTH (2023)

Article Public, Environmental & Occupational Health

Is neglect of self-clearance biasing TB vaccine impact estimates?

Danny Scarponi, Rebecca A. Clark, Chathika Krishan Weerasuriya, Jon Emery, Rein M. G. J. Houben, Richard White, Nicky McCreesh

Summary: Recent research suggests that self-clearance of Mycobacterium tuberculosis infection may be common, which could impact the potential impact of new tuberculosis vaccines. This study found that the inclusion of self-clearance in mathematical models increased the estimated relative reduction in incidence for vaccines effective only in uninfected individuals, but had variable effects on vaccines effective only in infected individuals. The inclusion of self-clearance had minimal impact on vaccines that work regardless of infection status.

BMJ GLOBAL HEALTH (2023)

Article Public, Environmental & Occupational Health

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

Rebecca A. Clark, Christinah Mukandavire, Allison Portnoy, Chathika K. Weerasuriya, Arminder Deol, Danny Scarponi, Andrew Iskauskas, Roel Bakker, Matthew Quaife, Shelly Malhotra, Nebiat Gebreselassie, Matteo Zignol, Raymond C. W. Hutubessy, Birgitte Giersing, Mark Jit, Rebecca C. Harris, Nicolas A. Menzies, Richard G. White

Summary: The study estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) under different delivery scenarios. It found that introducing new tuberculosis vaccines can significantly reduce cases and deaths, and a one-off vaccination campaign is crucial for rapid impact.

LANCET GLOBAL HEALTH (2023)

Article Public, Environmental & Occupational Health

A competency framework on simulation modelling-supported decision-making for Master of Public Health graduates

Rok Hrzic, Maria Vitoria Cade, Brian Li Han Wong, Nicky McCreesh, Judit Simon, Katarzyna Czabanowska

Summary: Developing a competency framework targeting Master of Public Health education, this study identified 20 competencies related to simulation model-supported decision-making in public health. The framework covers stakeholder engagement, problem definition, evidence identification, participatory system mapping, model creation and calibration, and the interpretation and dissemination of model results. The framework is instrumental in including simulation model-supported decision-making in public health training.

JOURNAL OF PUBLIC HEALTH (2023)

No Data Available